Wuhan Keqian Biology Co.Ltd(688526) recently said on the investor interaction platform of Shanghai stock exchange that the company will focus on the development of pet vaccines, diagnostic reagents, micro ecological reagents and new veterinary drugs, actively seek new growth points and balance the company’s income composition.
Wuhan Keqian Biology Co.Ltd(688526) said that the company’s live pig Pseudorabies Vaccine (HB-98 strain) and live pig pseudorabies heat-resistant protective agent vaccine (hb2000 strain) adopt pig derived endemic strains isolated in China, which have stronger adaptability and immunogenicity and are more suitable for China’s local pig breeding industry. At the same time, the company launched the Inactivated Porcine Pseudorabies Vaccine Prepared by using the porcine strain isolated from China, so as to become a rare enterprise in China’s veterinary biological products industry that can provide both live and Inactivated Porcine Pseudorabies Vaccine at the same time. The combination of live vaccine and inactivated vaccine can be used to purify pseudorabies in large-scale pig farms.
Wuhan Keqian Biology Co.Ltd(688526) said that the company has and is selling pet vaccines including quadruple canine vaccine and inactivated rabies vaccine. At present, the company is actively carrying out cat related vaccine research. The company has made a long-term layout and continuously increased investment in the pet field, and will continue to expand in the future, further enrich the company’s product structure in the pet sector and improve the company’s ability to resist market risks.
(China Securities Journal · China Securities Network)
